Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Akeso
- Target Recruit Count
- 642
- Registration Number
- NCT05990127
- Locations
- π¨π³
The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
π¨π³The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
π¨π³Cancer hospital, Chinese academy of medical sciences and Peking union medical college, Beijing, Beijing, China
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT05984277
- Locations
- π¬π§
Research Site, Truro, United Kingdom
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
- Conditions
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Registration Number
- NCT05948462
- Locations
- πΊπΈ
Texas Oncology, Dallas, Texas, United States
πΊπΈMessino Cancer Center, Asheville, North Carolina, United States
πΊπΈTennessee Oncology, Nashville, Tennessee, United States
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT05918107
- Locations
- π¨π³
Jilin Provincial Tumor Hospital, Changchun, China
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05911308
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
πΊπΈUNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
πΊπΈFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 233
- Registration Number
- NCT05904379
- Locations
- π¨π³
Shanghai Pulmonary Hospital, Shanghai, China
π¨π³Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 124
- Registration Number
- NCT05891080
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-08-08
- Target Recruit Count
- 356
- Registration Number
- NCT05870319
- Locations
- π¨π³
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 23
- Registration Number
- NCT05805631
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05800340
- Locations
- π¨π³
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guanzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.